Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

124IcG250

Preclinical

MMemorial Sloan Kettering Cancer Center

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Renal CancerActive, not recruiting

Renal CancerPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Renal Cancer

NCT01582204

Clinical

Trials by Indication[1]

Renal Cancer1 trial

Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT01582204·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 124IcG250. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 124IcG250. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMemorial Sloan Kettering Cancer Center

Related News